Engflag

Risdone LS

Quick links to important sections

Risdone LS

Risdone LS_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Risdone LS

Property Description
Active Ingredients Risperidone, Trihexyphenidyl
Form Oral Tablet
Pharmacological Class Second-Generation Antipsychotic, Anticholinergic Agent
Combination Type Fixed-Dose Combination (FDC)
Origin Synthetic

What Type of Medicine is Risdone LS?

Risdone LS is a synthetic, prescription-only medication formulated as an oral tablet, consistently categorized as a fixed-dose combination (FDC) product. This preparation strategically unites two distinct active ingredients, Risperidone and Trihexyphenidyl, within a single dosage unit. The "LS" designation is a differentiating factor, identifying this as a low-strength formulation intended to facilitate precise therapeutic adjustment, which is especially important for individuals who may require a slower, more controlled initiation of treatment. This FDC approach is a specific pharmacotherapeutic strategy recognized in the management of complex neuropsychiatric conditions.

Composition and Pharmacological Class of Risdone LS

The core composition of Risdone LS consists of Risperidone and Trihexyphenidyl, which belong to two separate, clinically recognized pharmacological classes. Risperidone is structurally classified as a second-generation antipsychotic (SGA), which acts primarily on central neurotransmitters. This component is designed to adjust the balance of chemical messengers in the brain. Trihexyphenidyl is defined as an anticholinergic agent (antimuscarinic), a class of compound that addresses certain involuntary bodily functions. The inclusion of this second component is a specific design feature of this FDC, setting it apart from single-agent Risperidone products.

General Purpose of the Risperidone and Trihexyphenidyl Combination

The general purpose of combining these two synthetic agents is to achieve therapeutic stabilization while proactively managing potential motoric side effects. The Risperidone component works to help restore balance to the signaling pathways in the brain. The primary function of the included Trihexyphenidyl is to prevent or reduce movement-related disturbances, known as extrapyramidal symptoms, that can sometimes result from the effects of the antipsychotic component. This FDC strategy aims for comprehensive support in situations where both neurotransmitter modulation and physical tolerance optimization are simultaneously required.

What side effects are possible with Risdone LS?

Possible Side Effects and Safety Information

The safety profile for this fixed-dose combination, containing the antipsychotic Risperidone and the anticholinergic Trihexyphenidyl, is defined by adverse reactions documented in official regulatory labeling.

Frequency and System Classification

Adverse reactions are classified by frequency and system. Very Common (ge 10%) effects documented for the Risperidone component include sedation (somnolence), headache, insomnia, and parkinsonism (movement-related disturbances). Common effects (ge 1% to < 10%) include dizziness, akathisia (restlessness), nausea, constipation, and dry mouth; the latter two are often associated with the anticholinergic component. Reactions are grouped by Nervous System Disorders and Gastrointestinal Disorders, among others.

Serious Adverse Reactions and Safety Constraints

The official labeling highlights rare but serious adverse reactions, including Neuroleptic Malignant Syndrome (NMS) and Tardive Dyskinesia (TD). There is also an increased risk of Cerebrovascular Adverse Events (CVAE), such as stroke, in older adults with dementia-related psychosis, a condition for which this medicine is not approved. Long-term use is associated with potential metabolic changes, including weight gain and hyperglycemia.

Safety constraints include a contraindication for use in patients with known uncontrolled narrow-angle glaucoma or conditions causing urinary retention due to the Trihexyphenidyl component. Certain effects, such as Orthostatic Hypotension, are noted as more likely during treatment initiation or dose escalation, according to official regulatory documentation.

Overdose and Emergency Response

Overdose: When to Seek Help

Official regulatory documents from agencies such as the FDA and EMA describe the core risks and management of overexposure to the active component of Risdone LS (risperidone). Overdose symptoms are typically concentrated in the central nervous system (CNS) and cardiovascular system, with cases classified as potentially serious.

Documented Overdose Manifestations

Symptoms reported in regulatory sources generally include severe drowsiness, excessive sedation, confusion, and observable involuntary movement disorders (extrapyramidal symptoms). More serious manifestations affect the heart and brain, specifically low blood pressure (hypotension), a dangerously fast or irregular heartbeat (tachycardia), and seizures or convulsions. Prolongation of the QT interval, an electrical activity measure of the heart, has also been noted.

Immediate Actions and Critical Warnings

Per official instructions, urgent, immediate medical attention is required for any suspected overdose. Emergency medical services must be contacted if the person has collapsed, is unresponsive or cannot be awakened, or experiences severe difficulty breathing or a seizure. In cases where the victim remains conscious and stable, the first step is to contact a poison control helpline for immediate guidance.

Management described in official prescribing information is primarily supportive, focusing on maintaining the patient's airway, breathing, and circulation, as no specific antidote is available. Vulnerable populations, particularly pediatric patients, have been noted in regulatory warnings as being susceptible to severe effects, including life-threatening events, from accidental overexposure.

Therapeutic Uses of Risdone LS

What Risdone LS Treats: Main Uses and Benefits

This medication is commonly used across conditions characterized by periods of heightened symptoms, such as Schizophrenia and acute manic episodes in Bipolar I Disorder. It is applied when groups of symptoms appear suddenly or fluctuate, including hallucinations, delusions, and severe disorganized thinking. This combination also supports specific patient groups, including children and adolescents, to ease severe irritability, aggression, and self-injurious behaviors associated with Autism Spectrum Disorder.

By managing these challenging and disruptive manifestations, the medication provides support that helps ease the overall symptom burden and assists with supporting functional stability. A key feature of this combination is its use for managing symptoms of increased neurological or muscular activity, specifically tremors, muscle stiffness, and subjective inner restlessness (akathisia), which may arise during treatment.

“The primary goal is to provide supportive relief that helps patients cope more steadily with difficult episodes and maintain a sense of stability when symptoms become more noticeable.”

Quick Fact: Relief for Antipsychotic-Induced Motor Disturbances (The formulation supports patient comfort by helping to ease involuntary physical symptoms often related to the primary treatment.)

Eligibility and Restrictions for Use

Risdone LS, a combination medication containing Risperidone and Trihexyphenidyl, is prescribed for specific psychiatric conditions, such as Schizophrenia and other mood disorders, and to manage associated movement side effects. However, its use is restricted for certain individuals due to potential risks.

Contraindications (Who Cannot Use)

Risdone LS is generally not recommended for individuals with the following conditions:

  • Allergy or Hypersensitivity to Risperidone, Trihexyphenidyl, or any other component of the medication.
  • Narrow-Angle Glaucoma, as the Trihexyphenidyl component may increase intraocular pressure.
  • Gastrointestinal Obstruction or Partial Obstructive Uropathy (urinary retention), as the medication can worsen these conditions.
  • Dementia-Related Psychosis in older adults, due to an increased risk of stroke and death.

Precautions (Use with Caution)

Close medical supervision and dose adjustments may be necessary for patients with:

  • Cardiovascular Conditions: History of heart attack, heart failure, or heart rhythm problems.
  • Liver or Kidney Disease, as these conditions can affect the drug's clearance from the body.
  • Parkinson's Disease, which may be exacerbated.
  • Epilepsy or a history of Seizures.
  • Diabetes or Dyslipidaemia, as the medication can affect blood sugar and lipid levels.
  • Neuroleptic Malignant Syndrome (NMS) history.

Age and Pregnancy/Breastfeeding:

Population General Guidance
Children Not recommended for children under 18 years unless specifically for certain indications in younger age groups (e.g., autism-related irritability) under specialist guidance.
Elderly Use with caution due to increased sensitivity to side effects like dizziness and low blood pressure.
Pregnancy Consult a doctor. Used only if the potential benefit justifies the potential risk to the fetus.
Breastfeeding Consult a doctor. The drug's components may pass into breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Risdone LS, a combination product containing risperidone and trihexyphenidyl, primarily involves agents that affect risperidone's metabolism and agents with additive pharmacologic effects. Regulatory agencies document clinically significant interactions that require specific precautions or dose adjustments.

Pharmacokinetic Interactions

Interacting Product Category Official Regulatory Constraint
Potent CYP2D6 Inhibitors (e.g., Fluoxetine, Paroxetine) Increases drug exposure; necessitates a reduction in the risperidone dose.
Potent CYP3A4/P-gp Inducers (e.g., Carbamazepine) Decreases drug exposure; necessitates an increase in the risperidone dose, potentially up to double.
H2-Receptor Antagonists (e.g., Cimetidine, Ranitidine) Increases the bioavailability of risperidone; caution is advised upon co-administration.

Pharmacodynamic Interactions

The co-administration with other medicines that share a functional effect is documented as requiring caution. This includes concomitant use with Centrally-Acting Drugs (including alcohol) due to the risk of additive central nervous system (CNS) depression. Caution is also necessary with agents that induce hypotensive effects or those known to prolong the QT interval or cause electrolyte imbalance. Furthermore, risperidone may antagonize the effects of dopamine agonists such as levodopa.

Mechanism of Action

Risdone LS operates through a dual-component mechanism to influence central nervous system (CNS) pathways and the motor control system via receptor antagonism.

Antagonism of Central Neurotransmitter Receptors

The primary mechanism involves the dual antagonism of CNS receptors, notably the dopamine D2 and serotonin 5- HT2A receptors. The molecule exhibits a greater affinity for 5- HT2A sites. This receptor antagonism in the limbic and cortical pathways reduces the signal transduction rate, resulting in altered output patterns in the neuronal pathways that regulate cognitive and emotional processing. Risperidone’s action is further characterized by a relatively rapid dissociation from the D2 receptor.

Anticholinergic Action on Motor Control Centers

The second mechanism is the antagonism of muscarinic acetylcholine receptors ( M1) located in the striatum. The primary component's D2 antagonism influences the relationship between dopaminergic and cholinergic input in the motor system. The M1 receptor antagonism reduces postsynaptic muscarinic activity, which serves to modulate this functional relationship, thereby influencing muscle tone and the coordination of voluntary movement. The combination of these two distinct mechanisms results in concurrent modulation of central signaling pathways and the motor control system.

Dosage and Administration Information

The guidelines for using the Risperidone/Trihexyphenidyl fixed-dose combination (FDC) tablet are defined by the required administration method, precise dose management, and specific patient condition rules.

Administration Scope

The established route for this medication is oral administration as a tablet. The FDC tablet must be swallowed whole with a liquid and is not intended to be crushed, chewed, or broken. This medicine can be taken with or without food.

The frequency pattern allows for the dose to be administered once a day or in divided doses (twice daily), as determined by the specific regimen. Regardless of the frequency, the dose should be taken at a consistent time each day.

Labeled Dosing and Procedural Structure

The use protocol centers on a gradual dose adjustment (titration) process, starting with a low initial amount of the Risperidone component, such as 2 mg per day. Dose increments are applied slowly, with at least 24 hours separating each change, until the maintenance range, typically 4 mg to 8 mg of Risperidone daily, is achieved.

Population-specific administration rules are applied for certain patient groups. For older adults, the starting dose and subsequent dose increments must be reduced (e.g., initial dose of 0.5 mg twice daily). Similarly, patients with severe kidney or liver impairment require a lower initial dose and a slower titration schedule. Treatment is intended for long-term maintenance but must be discontinued gradually via tapering.

Instruction Classifications (High-Level)

Field Classification
Administration method type Oral (Swallowed Tablet)
Frequency pattern Daily (Once or Twice Daily)
Regulatory basis Clinical protocols
Use-context constraints Requires slow, controlled dose titration and population-specific dose adjustments.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Risdone LS

Risdone LS is a combination of two medicines, risperidone and trihexyphenidyl. The research evidence comes from studies of the individual components, as well as trials specifically examining the clinical context of using an antipsychotic alongside an agent to address movement side effects. This overview summarizes what the research has explored and what is still being investigated.

Research Evidence for Schizophrenia and Related Psychotic Disorders

Risperidone was evaluated in numerous short-term and intermediate-term randomized controlled trials (RCTs), which compared it to a placebo (an inactive substance) or to other study regimens in adults and adolescents with conditions such as schizophrenia. Researchers primarily measured outcomes related to symptom intensity or variability using standardized psychiatric rating scales. Observational studies also tracked patient outcomes for longer periods, up to two years.

These studies report measurements of how symptoms evolved, showing patterns related to changes in overall illness severity and in positive and negative symptoms. Researchers also tracked outcomes reflecting daily functioning or activity level. The evidence base for the risperidone component is extensive in the regulatory record, supported by a significant volume of controlled trials.

Long-term effects are not fully established regarding the functional and cognitive outcomes of this type of medication regimen. Direct comparative evidence is lacking for certain dosing strategies involving the fixed-dose combination, and subgroup findings are uncertain in some instances.

Research Evidence for Managing Movement Side Effects (EPS)

The research on trihexyphenidyl involves controlled trials and observational studies of patients who are receiving an antipsychotic and who are experiencing or are at high risk for movement disorders. These trials applied in studies examining patient-reported outcomes describing perceived discomfort. Findings show patterns related to physical discomfort outcomes that were monitored. The evidence for using trihexyphenidyl in the context of acute EPS is described as extensively documented in the research record.

However, the scientific support for the routine, long-term use of this type of medicine to prevent EPS (prophylaxis) is limited and heterogeneous. There is limited information for long-term outcomes regarding the effects of fixed-dose combination use, particularly concerning potential impacts on cognitive function. The evidence for its routine use over long periods is generally limited compared to the evidence for acute, emergent symptoms.

Evidence in Specific Patient Groups

The risperidone component was studied for both adolescents and adults with schizophrenia. Evidence largely focuses on general adult populations for the trihexyphenidyl component. Data for certain groups, such as older adults, remains insufficient in the context of fixed-dose combinations. The results apply only to the populations studied in the regulatory trials, and information for other subgroups is uncertain.

Key Limitations and Unanswered Research Questions

The key limitation is that the fixed-dose combination has not been directly compared to risperidone monotherapy with as-needed use of an anticholinergic. This means comparative evidence is lacking to fully determine the advantages of the combination in all clinical scenarios. Sample sizes were modest in some studies, and evidence quality varies across studies that track functional outcomes. Furthermore, the question of the optimal duration for using the trihexyphenidyl component remains an area where research is ongoing, and scientific reviews note ongoing research regarding the duration of use for these agents.

Key Studies & References

  1. Psychosis and schizophrenia in adults: prevention and management (NICE Guideline CG178)
  2. Recognition and Management of Antipsychotic-induced Movement Disorders
  3. Clinical Review Update: Concomitant Anticholinergic and Antipsychotic Use (Focus on Long-Term Cognitive Risks)

Frequently Asked Questions (FAQ)

Common questions about Risdone LS (FAQ)

Q: Why did my doctor prescribe me Risdone LS instead of just an antidepressant?

A: This medication is categorized as an antipsychotic combined with an anticholinergic agent, which places it in a different class than standard antidepressants. Official product information indicates that it is used for the management of conditions such as schizophrenia and bipolar disorder. Its mechanism of action influences chemical messengers like dopamine and serotonin in the brain, which is distinct from the primary action of many other drug classes.

Q: Will Risdone LS interact with my allergy medication?

A: Caution is required when combining this medication with other medicines that have additive effects. Since this product contains an anticholinergic agent, co-administration with other drugs that share this effect (such as some allergy medications) may increase the risk of side effects like dry mouth, blurred vision, and difficulty urinating. It is important that all co-administered medications are reviewed by a healthcare professional.

Q: How long do people usually stay on Risdone LS?

A: Regulatory information indicates that treatment with the risperidone component is used for both acute and maintenance treatment of certain conditions, suggesting long-term use is common. The duration of therapy is determined by the prescribing healthcare professional, and the long-term risks and benefits are typically reassessed over time.

Q: Why is Risdone LS sometimes prescribed with another mood stabilizer?

A: The risperidone component of this medicine is specifically indicated as adjunctive therapy, meaning it is used in addition to another medication, for the short-term treatment of acute manic or mixed episodes associated with Bipolar I Disorder. This combination typically involves taking it alongside traditional mood stabilizers like lithium or valproate to manage the condition.

Q: Why do some people say Risdone LS makes them feel 'flat' emotionally?

A: Regulatory documents note that the medication has the potential to impair thinking and judgment. Some research on antipsychotics also notes that these medicines can lead to effects described as emotional blunting or cognitive dulling with extended use. This outcome is understood to be related to how the medicine modifies chemical signaling in the brain.

Q: What is the purpose of the low-dose formulation in Risdone LS?

A: The official protocol for using this medicine requires a gradual dose adjustment process known as titration. A low-dose formulation helps accommodate the requirement for slow, gradual dose adjustment, particularly for patient groups such as older adults or those with impaired kidney or liver function, where lower starting doses are necessary.

Q: What are the benefits of Risdone LS compared to just Risperidone?

A: This medicine is a fixed-dose combination of an antipsychotic (risperidone) and an anticholinergic agent (trihexyphenidyl). The trihexyphenidyl component is included to address the risk of movement side effects, known as extrapyramidal symptoms (EPS), that may result from the antipsychotic component.

Q: Is it safe to suddenly stop taking Risdone LS?

A: Official procedures specify that the treatment is to be discontinued gradually by following a tapering schedule, rather than stopping abruptly. Abrupt withdrawal should be avoided, as it may result in rebound or withdrawal effects, including an acute worsening of parkinsonism symptoms.

Q: Does Risdone LS interact with alcohol?

A: Yes. Regulatory information states that alcohol should be avoided because of the risk of additive central nervous system (CNS) depression. This combination can cause increased drowsiness, dizziness, and greater impairment of thinking and motor skills.

Q: Can Risdone LS affect my concentration at work or school?

A: Official warnings state that this medicine has the potential to impair judgment, thinking, and motor skills, and may cause drowsiness. Activities requiring mental alertness, such as operating machinery or driving, should be avoided until an individual knows how this medicine affects their cognitive and motor skills.

Q: What kind of research has been done on the long-term effects of Risdone LS?

A: Research associated with this drug class includes studies tracking metabolic changes over time, such as weight gain, high blood sugar, and elevated lipid levels. Studies also monitor hormonal changes like hyperprolactinemia (elevated prolactin). Direct long-term data for the fixed-dose combination's functional outcomes is limited, but research on the individual components is extensive.

Q: Is Risdone LS addictive or habit-forming?

A: The risperidone component is not classified as a controlled substance. However, the trihexyphenidyl component is noted in its regulatory labeling to have the potential for misuse due to the risk of psychiatric disturbances, which may lead to dependence.

Q: Can Risdone LS impact fertility or reproductive health?

A: Official information indicates that the risperidone component can cause hyperprolactinemia, or elevated prolactin levels, which may lead to sexual dysfunction, menstrual irregularities, or unexpected breast tissue changes. Nonclinical studies in animals also showed potential for impaired fertility.

Q: Is it normal to have vivid dreams when starting Risdone LS?

A: While the official list of very common side effects includes insomnia and sedation, some patient-focused materials note that changes in sleep patterns, including vivid dreams, have been reported. Any persistent or bothersome changes in sleep or mood are factors that a healthcare provider should be made aware of.

Q: Why do some forums discuss the risk of EPS with Risdone LS?

A: The risperidone component of the medicine is an antipsychotic known to cause Extrapyramidal Symptoms (EPS), which include movement disorders like tremors, stiffness, and restlessness. These are listed as common side effects. The trihexyphenidyl component is specifically added to the formulation to manage and address the risk of these movement side effects.

Q: What should I avoid eating or drinking while on Risdone LS?

A: The regulatory label requires that alcohol is avoided due to the risk of additive central nervous system (CNS) depression. No specific foods are listed in the regulatory documents that must be strictly avoided, and the tablet can be taken with or without food.

Q: Will Risdone LS make me more sensitive to the sun?

A: The anticholinergic component of this medicine may impair the body’s ability to regulate temperature by sweating. This means there is an increased risk of overheating (hyperthermia) in hot weather or during strenuous exercise. Patients taking this medicine may need to take precautions regarding prolonged sun exposure.

Q: What kind of mental health conditions are typically treated with Risdone LS?

A: The risperidone component is approved for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder, and irritability associated with autistic disorder. The combination is used in the context of these conditions to stabilize mood while managing potential movement side effects.

How should Risdone LS be stored and disposed of?

Official Storage Requirements

Risdone LS tablets must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). The medication must be protected from both excessive heat and moisture and should never be frozen. Tablets are required to be kept in a tightly closed container to maintain integrity. A critical safety requirement is that the product must be stored out of the reach of children and pets at all times.

Official Disposal Instructions

Unused or expired Risdone LS should be disposed of according to established pharmaceutical waste guidelines. Regulators strongly recommend utilizing official drug take-back programs or authorized collection sites when available. The medication must not be flushed down the toilet or disposed of in wastewater. If a take-back program is unavailable, the tablets should be mixed with an unappealing substance, sealed in a container, and placed in the household trash. Any personal information on the prescription label must be removed or obscured before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Risdone LS found in:

A-Z Index: